Lantheus scored a tentative FDA approval for an ANDA for PNT2003, a generic version of Novartis’ radioligand Lutathera (lutetium‑177 dotatate), while Novartis maintains active patent litigation dating to 2024. The tentative nod recognizes bioequivalence but full commercialization faces legal hurdles: Novartis sued to protect formulation and process patents, prompting a complex Hatch‑Waxman dispute and an ongoing Delaware court proceeding. The lead sentence: the FDA issued tentative approval, setting up a high‑stakes IP showdown that will determine when a Lutathera generic can enter market. The story cites Judge Maryellen Noreika’s remark about the unusually contentious case and outlines how radiopharmaceuticals rely heavily on formulation and process patents rather than novel core molecules.